Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
Merck takes on the TROP2 leaders again in breast cancer
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
Amgen looks for Five Prime payback
A key pivotal study of bemarituzumab will read out shortly.
Yet more conjugates enter the clinic
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
Chimerix's cancer transformation
US approval could mark the company's graduation to oncology.
ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
